Pretty fair assumption to make re sales figures from the (previous) Standard of Care Relyvrio and because PharmAust had better results, albeit, 12 patients, we could expect to generate similar if not, better revenue than Amylyx Pharmaceuticals... ~$1B p/a
Save face and move forward. Writing is already in black and white!
Ann: Media clarification, page-9
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.010(4.44%) |
Mkt cap ! $114.3M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.5¢ | 23.0¢ | $57.36K | 247.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49594 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 31489 | 2 |
View Market Depth
| Last trade - 10.51am 21/10/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |